Premium
Maxillectomy and targeted radionuclide therapy with 153Sm‐EDTMP in a recurrent canine osteosarcoma
Author(s) -
Moe L.,
Boysen M.,
Aas M.,
Lønaas L.,
Gamlem H.,
Bruland Ø. S.
Publication year - 1996
Publication title -
journal of small animal practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.7
H-Index - 67
eISSN - 1748-5827
pISSN - 0022-4510
DOI - 10.1111/j.1748-5827.1996.tb01782.x
Subject(s) - medicine , radionuclide therapy , osteosarcoma , surgery , white blood cell , pathology
An eight‐year‐old dog with a local relapse of an osteosarcoma was treated with partial maxillectomy and systemic radionuclide therapy that involved two injections, 43 and 45 megabec‐querels per kg bodyweight of the bone‐seeking agent samarium‐153‐ethylenediaminetetramethy‐lene phosphonic acid ( 153 Sm‐EDTMP), 15 weeks apart. A transient drop in white blood cell count and platelet count was observed following each 153 Sm‐EDTMP treatment. Follow‐up 21 months after surgery revealed no evidence of local recurrence or metastases. The dog was in excellent condition, suffering only minor sequelae from the surgical procedure. Compared with historical controls treated with surgery alone, the combination of surgery and systemic radionuclide therapy seems a promising strategy for the treatment of canine osteosarcoma.